WeVote
Log In

Bill

Bill

HB 406

Health Care - As introduced, lowers from every three years to every two years, the time within which the advisory committee composed of medical device industry representatives and a representative of the department of economic and community development must review rules regarding the board of pharmacy's oversight of facilities that manufacture, warehouse, and distribute medical devices in order to review the advancements of new medical device technologies. - Amends TCA Title 8; Title 47; Title 56; Title 63 and Title 71.

114th Regular Session (2025-2026) Introduced by Brock Martin

Requires medical device facility oversight rules be reviewed every 2 years instead of 3 to track technological advancements, with an industry-heavy advisory committee conducting reviews.

Taken off notice for cal in s/c Finance, Ways, and Means Subcommittee of Finance, Ways, and Means Committee
#healthcare
0
WeVote Research Nonpartisan
Bill Summary · HB 406

Legislative bill overview

HB 406 shortens the regulatory review cycle for medical device manufacturing and distribution facilities from every three years to every two years. An advisory committee composed of medical device industry representatives and a state economic development official would conduct these reviews to assess how pharmacy board oversight rules align with technological advancements.

Why is this important

More frequent regulatory reviews can help ensure state rules keep pace with rapid innovation in medical device technology, potentially reducing barriers to bringing new devices to market. Conversely, more frequent reviews increase administrative burden on regulators and create more opportunities for industry input into rules that govern their sector.

Potential points of contention

  • Industry influence: The advisory committee is composed primarily of medical device industry representatives, raising questions about whether rule reviews will prioritize industry convenience over consumer safety and pharmacy oversight effectiveness
  • Regulatory burden: More frequent review cycles (every 2 years instead of 3) require more staff time and resources from the Board of Pharmacy and Department of Economic and Community Development without apparent funding increases
  • Pharmacy board autonomy: Requiring more frequent external reviews of the Board of Pharmacy's rules may limit the board's independent judgment in protecting public health through appropriate facility oversight

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.